Background Exposure to anthracyclines (ANT) during childhood represents a high risk for
development of late cardiotoxicity. Cardiotoxicity is usually detected only when clinical …

Background Anthracyclines are widely used in the treatment of pediatric cancer but their use
is associated with cardiotoxicity. The cardiotoxic effect may become clinically apparent many …

Background Anthracycline‐induced cardiotoxicity can cause serious health problems for an
increasing number of survivors of childhood malignancies. The aims of this study were to …

BACKGROUND: The incidence of subclinical cardiotoxicity following anthracycline treatment
for childhood cancer varies according to the method used for its detection. The aim of the …

Background. Childhood cancer survivors treated with anthracyclines and mediastinal
irradiation are at risk for late onset cardiotoxicity. Aims of the Study. To assess the role of N …

Background and aim: Our aims were to investigate the utility of plasma N terminal-pro B-type
natriuretic peptide (NT-proBNP) level and find the most beneficial echocardiographic …

Background: The aim of this study was to assess the value of N-terminal pro-brain natriuretic
peptide (NT-proBNP) in predicting late cardiotoxicity in patients treated with not-high-dose …

Objective: To investigate the cardiotoxicity indexes in children with malignant tumors after
the administration of anthracycline (ANT) chemotherapy. Materials and Methods: Data from …

Objective Anthracyclines are well established as highly efficacious antineoplastic agents for
childhood malignancy, but they frequently cause dose-related cardiotoxicity. For this reason …

Aim The role that plasma N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) and cardiac
troponins T (cTnT) and I (cTnI) play in supplementing imaging to screen for cardiac late …